Taiwan Liposome Company Overview
Latest ROE for Taiwan Liposome Company: -532.12% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-532.12%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, TLC shows a ROE of -532.12%. That is below the Healthcare sector average of 29.39%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.39%. Taiwan Liposome Company is at -532.12%, which is lower that average. That is roughly 1910.5% below the sector mean. Use the comparison chart on this page to see how TLC stacks up against individual peers as well.
Check the historical chart to see whether TLC's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Taiwan Liposome Company with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Taiwan Liposome Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -532.12%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.39%, while TLC is at -532.12%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
